About the Company
Larimar Therapeutics, Inc., is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company's lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for FA. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Employees
28
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $LRMR News
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
Positive top-line data from Phase 2 dose exploration study of nomlabofusp, which was generally well-tolerated, with dose-dependent increases in ...
5 Stocks that Analysts Love in March 2024
Today, we will look at 5 stocks that analysts are highly bullish about in March 2024. Analysts have recently given a Buy ...
Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks
In this article, we will take a detailed look at the Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks. For a ...
Larimar Triumphs: Significant Strides Made on the Road to Treating Friedreich's Ataxia
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR), a company dedicated to transforming the lives of patients ...
Buy Rating on Larimar Therapeutics Backed by Promising Drug Progress for Friedreich’s Ataxia
LifeSci Capital analyst Cory Jubinville, PhD has maintained their bullish stance on LRMR stock, giving a Buy rating today. Cory Jubinville, ...
Larimar: Q4 Earnings Snapshot
BALA CYNWYD, Pa. (AP) — BALA CYNWYD, Pa. (AP) — Larimar Therapeutics, Inc. (LRMR) on Thursday reported a loss of $13 million in its fourth quarter. On a per-share basis, the Bala Cynwyd, ...
Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results
Net Loss: Reported a net loss of $13.0 million in Q4 2023, and $36.9 million for the full year. Research and Development Expenses: Increased to $10.6 million in Q4 2023, primarily due to higher drug ...
Recap: Larimar Therapeutics Q4 Earnings
Larimar Therapeutics LRMR reported its Q4 earnings results on Thursday, March 14, 2024 at 04:05 PM. Here's what investors need to know about the announcement. Larimar Therapeutics missed estimated ...
Altimmune falls after Q4 results; obesity drug data released
Altimmune (NASDAQ:ALT) shares lost ~21% premarket Wednesday after the company shared mid-stage data for its obesity candidate ...
Altimmune GAAP EPS of -$0.54 misses by $0.16
GAAP EPS of -$0.54 misses by $0.16. Revenues of $37K. Altimmune had cash, cash equivalents and short-term investments totaling $198.0 million at December 31, 2023.
Loading the latest forecasts...